X
[{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Combination Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-line Mantle Cell Lymphoma in ECHO Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Plus Chemoimmunotherapy Reduces Progression Risk in Lymphoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Acerta Pharma
Filters
Companies By Therapeutic Area
Details:
Calquence (acalabrutinib) is a next-generation, selective inhibitor of bruton’s tyrosine kinase (BTK). It is being evaluated for the treatment of mantle cell lymphoma in adults.
Lead Product(s):
Acalabrutinib ,Bendamustine Hydrochloride ,Rituximab
Therapeutic Area: Oncology
Product Name: Calquence
Highest Development Status: Phase III
Product Type: Small molecule
Recipient:
AstraZeneca
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 16, 2024
Details:
Calquence (acalabrutinib) is a next-generation, selective inhibitor of bruton’s tyrosine kinase (BTK). It is being evaluated for the treatment of mantle cell lymphoma in adults.
Lead Product(s):
Acalabrutinib ,Bendamustine Hydrochloride ,Rituximab
Therapeutic Area: Oncology
Product Name: Calquence
Highest Development Status: Phase III
Product Type: Small molecule
Recipient:
AstraZeneca
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 02, 2024
Details:
Companies will study the combination of Ascentage's APG-2575 and Acerta's CALQUENCE® (acalabrutinib), evaluating the efficacy and safety of this combination therapy in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Lead Product(s):
Lisaftoclax ,Acalabrutinib
Therapeutic Area: Oncology
Product Name: APG-2575
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Ascentage Pharma
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
June 21, 2020